首页> 外文期刊>Journal of pharmacy practice >The Use of Kcentra ? in the Reversal of Coagulopathy of Chronic Liver Disease
【24h】

The Use of Kcentra ? in the Reversal of Coagulopathy of Chronic Liver Disease

机译:使用kcentra? 在慢性肝病凝血病的逆转中

获取原文
获取原文并翻译 | 示例
           

摘要

We aim to describe our experience with the four-factor prothrombin complex concentrates (4F-PCC) Kcentra ? at differing doses in patients with liver cirrhosis requiring emergent hemostasis in the setting of major or life-threatening bleeding. An automated query of patients who received Kcentra between January 2014 and March 2016 was performed. Patients who had clinically significant bleeding and received Kcentra for treatment of coagulopathy of chronic liver disease (CCLD) were included in the study. Baseline patient demographics, administration indication, pertinent laboratory values, and other reversal therapies were collected. Four patients met inclusion for analysis. One patient presented with hemopericardium, cardiac tamponade, and shock, and 3 patients presented with intracranial hemorrhage. Each patient experienced an improvement in international normalized ratio (INR) and at least a period of clinical hemostasis after Kcentra administration without complications referable to Kcentra. Kcentra may be a safe, rapid, and effective treatment option for hemorrhagic emergencies associated with CCLD. Further research is needed to determine the ideal monitoring and dosing regimen for use in CCLD.
机译:我们的目标是描述我们用四因素凝血酶原浓缩物(4F-PCC)Kcentra的经验?在肝硬化患者中不同剂量,需要突出的止血,在威胁危及的出血的环境中。在2014年1月至2016年3月间接受Kentra的自动查询是在2016年1月至2016年3月之间进行的。研究中含有临床显着出血和接受KENTA治疗慢性肝病(CCLD)凝血病的患者。基线患者人口统计,管理指示,相关实验室值和其他逆转疗法被收集。四名患者符合分析。一名患者患有血液术,心脏棉签和休克,3例患有颅内出血的3例。每位患者在KENTRA管理后,每次归一化比率(INR)的改善和至少一段时间的临床止血,无需对KENTA的并发症。 Kcentra可能是与CCLD相关的出血紧急情况的安全,快速和有效的治疗选择。需要进一步研究以确定用于CCLD的理想监测和给药方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号